Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nano mRNA Co., Ltd. (4571:JPX), powered by AI.
Nano mRNA Co., Ltd. is currently trading at ¥105. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Nano mRNA Co., Ltd. on Alpha Lenz.
Nano mRNA Co., Ltd.'s P/E ratio is -8.9.
“Nano mRNA Co., Ltd. trades at a P/E of -8.9 (undervalued) with modest ROE of -27.1%.”
Ask for details →Nano mRNA Co., Ltd. is a prominent player in the biotechnology sector, specializing in the development and commercialization of mRNA-based therapeutics. The company's primary function is to harness the power of messenger RNA to create innovative healthcare solutions, particularly focusing on vaccines and treatments for cancer, infectious diseases, and rare genetic disorders. By translating mRNA technology into practical medical applications, Nano mRNA Co., Ltd. aims to address some of the most pressing health challenges globally. Notable features of the company include its advanced research and development facilities and strategic partnerships with academic institutions and pharmaceutical companies, which bolster its innovation capabilities. The company’s expertise in mRNA technology places it at the forefront of the rapidly evolving biotech industry, a sector characterized by its significant research investments and high regulatory standards. In the financial market, Nano mRNA Co., Ltd. holds a significant position due to its cutting-edge contributions to modern medicine and potential for growth amidst the increasing acceptance and application of mRNA technology across various therapeutic areas.
“Nano mRNA Co., Ltd. trades at a P/E of -8.9 (undervalued) with modest ROE of -27.1%.”
Ask for details →Nano mRNA Co., Ltd. (ticker: 4571) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 20 employees. Market cap is $7.4B.
The current price is 105 with a P/E ratio of -8.86x and P/B of 2.7x.
ROE is -27.12% and operating margin is -696.07%. Annual revenue is $109M.